NextCure (NASDAQ:NXTC) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of NextCure (NASDAQ:NXTC) from a sell rating to a hold rating in a report published on Saturday.

Several other research firms have also commented on NXTC. Weiss Ratings raised shares of NextCure from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday. Zacks Research upgraded shares of NextCure from a “strong sell” rating to a “hold” rating in a research report on Thursday, June 11th. Finally, HC Wainwright reissued a “buy” rating on shares of NextCure in a research note on Thursday. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, NextCure currently has a consensus rating of “Hold” and an average target price of $19.00.

NextCure Stock Performance

NXTC opened at $8.21 on Friday. The firm has a market cap of $29.64 million, a P/E ratio of -0.94 and a beta of 1.27. NextCure has a 52-week low of $1.55 and a 52-week high of $15.74. The business’s fifty day moving average is $3.80 and its 200-day moving average is $8.24.

NextCure (NASDAQ:NXTC) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($2.80) EPS for the quarter, missing analysts’ consensus estimates of ($1.95) by ($0.85). On average, research analysts predict that NextCure will post -8.11 earnings per share for the current fiscal year.

Insider Activity at NextCure

In related news, major shareholder Adar1 Capital Management, Llc bought 292,850 shares of the company’s stock in a transaction dated Thursday, July 30th. The stock was purchased at an average price of $4.93 per share, with a total value of $1,443,750.50. Following the completion of the acquisition, the insider owned 686,116 shares of the company’s stock, valued at $3,382,551.88. The trade was a 74.47% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have bought a total of 346,761 shares of company stock valued at $1,710,807 over the last three months. 11.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On NextCure

Institutional investors have recently added to or reduced their stakes in the stock. Ikarian Capital LLC acquired a new stake in NextCure in the fourth quarter valued at approximately $3,382,000. Squadron Capital Management LLC acquired a new position in shares of NextCure during the fourth quarter worth $3,363,000. Exome Asset Management LLC acquired a new position in shares of NextCure during the fourth quarter worth $2,341,000. AWM Investment Company Inc. bought a new position in shares of NextCure in the 4th quarter valued at $1,665,000. Finally, Cable Car Capital LP lifted its stake in shares of NextCure by 13.1% in the 2nd quarter. Cable Car Capital LP now owns 758,141 shares of the company’s stock valued at $349,000 after acquiring an additional 88,040 shares during the last quarter. 42.65% of the stock is currently owned by institutional investors and hedge funds.

About NextCure

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.